Xtant Medical Holdings, Inc.
Rank #9Op. LeverageXTNT · NYSE · Healthcare
Xtant Medical Holdings, Inc. (XTNT) — Rank #9 by gross profitability (GP/assets 1.06) · ROE 12.4% · Piotroski F-Score 8 / 9.
As-of 2026-09-28 · CIK 0001453593 · all metrics point-in-time as of the filing date.
About
Xtant Medical Holdings, Inc. provides regenerative medicine products and medical devices for orthopedic and neurological surgeons in the United States and internationally.
Show moreShow less
It offers OsteoSponge, a natural scaffold for cellular in-growth; OsteoSelect DBM Putty, a moldable demineralized bone matrix; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated and terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor Pro, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, an aseptically processed and viable bone allograft; and nanOss products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier. It also provides sports allografts for anterior and posterior cruciate ligament repairs, anterior cruciate ligament reconstruction, and meniscal repair; milled spinal allografts for cortical bone milled to desired shapes and dimensions; and traditional allografts for orthopedics, neurology, podiatry, oral/maxillofacial, genitourinary, and plastic/reconstructive applications. In addition, it offers cervical products comprising Spider cervical plating, Streamline OCT system, and CervAlign systems; thoracolumbar products, such as of Axle-X interspinous fusion, Streamline MIS spinal fixation, Streamline TL spinal fixation, and HPS 2.0 hybrid performance systems; Silex sacroiliac joint fusion systems; interbody products comprising Calix for cervical and thoracolumbar applications, Irix-C Cervical and Irix-A lumbar integrated dusion systems, and Fortilink implants; Contact ALP (Anterior Lumbar Plate) System; and interlaminar stabilization products, such as Coflex device for lumbar spinal stenosis; and CoFix implants for back and disc pain.
The company is headquartered in Belgrade, Montana.
- Industry
- Medical Devices
- Sector
- Healthcare
- State
- DE
- Filer Category
- Non-accelerated filerSmaller reporting company
- Fiscal Year End
- December 31
- Website
- xtantmedical.com
Financials
Each fiscal year is read as-of that year’s own 10-K filing, so nothing restated after the fact leaks backwards. Line items this filer never tagged are omitted. Hover or tap a badge for the diagnostic behind it.
| Fiscal year end | 2025-12-31filed 2026-03-31 | 2024-12-31filed 2025-03-06 | 2023-12-31filed 2024-04-01 | 2022-12-31filed 2023-03-07 |
|---|---|---|---|---|
| Revenue | 133.9 | 117.3 | 91.3 | 58.0 |
| Revenue growth (YoY) | 14.2% | 28.4% | 57.5% | 4.9% |
| Cost of revenue | 49.7 | 49.1 | 35.8 | 25.8 |
| Gross profit | 84.3 | 68.2 | 55.5 | 32.1 |
| Gross margin | 62.9% | 58.2% | 60.8% | 55.4% |
| Research & development | 2.1 | 2.4 | 1.3 | 0.9 |
| Operating income | 7.3 | (12.1) | (10.2) | (6.8) |
| Operating margin | 5.4% | -10.3% | -11.1% | -11.7% |
| Interest income | 0.1 | — | 0.1 | 0.0 |
| Interest expense | 3.7 | 4.2 | 2.9 | 1.7 |
| Pre-tax income | 7.0 | (16.3) | (1.0) | (8.4) |
| Income tax expense | 2.0 | 0.2 | (1.7) | 0.1 |
| Net income | 5.0 | (16.4) | 0.7 | (8.5) |
| Net margin | 3.7% | -14.0% | 0.7% | -14.6% |
| EPS (basic) | $0.04 | -$0.12 | $0.01 | -$0.09 |
| EPS (diluted) | $0.03 | -$0.12 | $0.01 | -$0.09 |
Figures are as originally filed with the SEC (point-in-time), not restated, so they can differ slightly from sites that show later-restated numbers. Why point-in-time?